Aurinia Pharmaceuticals (AUPH) 4Q Catalyst Coming Into View - HCWainwright
Tweet Send to a Friend
H.C. Wainwright analyst Ed Arce reiterated a Buy rating and $15.00 price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) after management ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


